个体化免疫抑制抗凝疗法在抗心磷脂抗体阳性胎儿生长受限治疗中的应用  

The application of individualised immune-suppression and anticoagulant in therapy of FGR with ACA

作　　者：陈泳珊[1] 周小玲[1] 曹伍兰[1] 苏园园[1] 

机构地区：[1]中山市人民医院妇产科,中山528403

出　　处：《中国优生与遗传杂志》2012年第8期76-77,共2页Chinese Journal of Birth Health & Heredity

摘　　要：目的探讨个体化免疫抑制抗凝疗法在抗心磷脂抗体阳性胎儿生长受限治疗中的应用。方法选择2008年1月至2010年12月在我院诊断为胎儿生长受限且抗心磷脂抗体阳性孕妇80例为研究对象,随机分为两组:个体化免疫抑制抗凝疗法组和常规治疗组各40例。记录分娩情况。结果免疫抑制抗凝疗法组胎儿双顶径、股骨长增加、出生体重均明显高于常规治疗组(P<0.05)两组在分娩时间上无明显差别。两组均无明显副反应出现。结论根据FGR患者的具体情况给予个体化治疗,才能提高疗效。Objective ： To investigate the application of individualised immune - suppression and anticoagulant in therapy of FGR with ACA （anticardiolipin antibody）. Methods： From January of 2008 to December of 2010, eighty FGR women with antieardiolipin antibody were selected, 40 pregnancy women were received the individual therapy, other 40 eases were received regular therapy. We follow up their pregnancy outcome. Results： The fetal BPD , FL and birth weight in individual group were significantly higher than in regular group. There were no difference on pregnancy time, and no case of significant adverse effects to be found. Conclusion ： The individual therapy were effective.

关 键 词：胎儿生长受限 抗心磷脂抗体 阿司匹林 肝素 

分 类 号：R714.5[医药卫生—妇产科学]